• By ICR Secretariat
  • Posted Thursday, July 21, 2022

AstraZeneca continues Farxiga push, enlists Health2Sync for a digital approach to diagnosing kidney disease

https://www.fiercepharma.com/marketing/astrazeneca-continues-farxgia-push-enlists-health2sync-digital-approach-diagnose-kidney

AstraZeneca is going all out for its new Farxiga kidney disease label: This year, it’s already started a new DTC campaign for the drug, and it more recently highlighted the “silent” nature of the disease in a new survey campaign.